v3.25.4
Segment, Geographic and Other Revenue Information - Revenues by Product (Detail) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Revenue from External Customer [Line Items]      
Revenues: [1] $ 62,579 $ 63,627 $ 59,553
Alliance revenues 9,266 8,388 7,582
Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 61,199 62,400 58,237
Biopharma [Member] | U.S. Commercial Division      
Revenue from External Customer [Line Items]      
Revenues: [2] 36,708 38,332 27,749
Biopharma [Member] | International Commercial Division      
Revenue from External Customer [Line Items]      
Revenues: 24,491 24,068 30,488
Pfizer CentreOne [Member]      
Revenue from External Customer [Line Items]      
Revenues: [3] 1,338 1,146 1,272
Pfizer Ignite [Member]      
Revenue from External Customer [Line Items]      
Revenues: 41 82 44
Total Alliance revenues [Member]      
Revenue from External Customer [Line Items]      
Alliance revenues 9,266 8,388 7,582
Royalty [Member]      
Revenue from External Customer [Line Items]      
Revenues 1,650 1,423 1,058
Primary Care [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 26,820 30,135 30,799
Primary Care [Member] | Eliquis [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [4] 7,961 7,366 6,747
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 6,494 6,411 6,501
Primary Care [Member] | Comirnaty [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 4,367 5,353 11,220
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [5] 2,362 5,716 1,279
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 1,424 1,263 928
Primary Care [Member] | Abrysvo [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 1,033 755 890
Primary Care [Member] | FSME-IMMUN/TicoVac [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 319 280 268
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 2,860 2,991 2,968
Specialty Care [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 17,546 16,652 14,988
Specialty Care [Member] | Vyndaqel Family [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 6,380 5,451 3,321
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 1,087 1,168 1,703
Specialty Care [Member] | Sulperazon (Outside the U.S. and Canada) [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 653 637 757
Specialty Care [Member] | Inflectra [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 646 509 490
Specialty Care [Member] | Zavicefta (Outside the U.S. and Canada) [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 638 586 511
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 627 690 830
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 446 470 539
Specialty Care [Member] | Octagam [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 418 509 245
Specialty Care [Member] | Zithromax [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 399 480 406
Specialty Care [Member] | Cresemba [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 349 281 195
Specialty Care [Member] | Cibinqo [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 284 215 128
Specialty Care [Member] | All other Hospital [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 4,030 4,167 4,514
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 1,588 1,489 1,350
Oncology [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 16,834 15,612 12,450
Oncology [Member] | Ibrance [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 4,122 4,367 4,753
Oncology [Member] | Xtandi [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [6] 2,194 2,039 1,659
Oncology [Member] | Padcev [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 1,940 1,588 53
Oncology [Member] | Oncology Biosimilars [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [7] 1,301 1,037 1,407
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 1,023 731 539
Oncology [Member] | Inlyta [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 923 978 1,036
Oncology [Member] | Adcetris [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [8] 907 1,089 56
Oncology [Member] | Braftovi/Mektovi [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [9] 716 607 477
Oncology [Member] | Bosulif [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 611 645 645
Oncology [Member] | Tukysa [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 463 480 18
Oncology [Member] | Aromasin [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 450 347 301
Oncology [Member] | Orgovyx [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: [10] 421 201 120
Oncology [Member] | Elrexfio [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 304 133 10
Oncology [Member] | Talzenna [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 182 117 64
Oncology [Member] | Tivdak [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: 147 131 4
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]      
Revenue from External Customer [Line Items]      
Revenues: $ 1,127 $ 1,122 $ 1,308
[1] Revenues are primarily attributed to countries based on the location of the customer.
[2] Refer to Note 17A above
[3]
(h)PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.
[4] Reflects alliance revenues and product revenues.
[5] 2024 included (i) a $771 million favorable final adjustment recorded in the first quarter to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023, and (ii) $442 million of revenue recorded in the third quarter in connection with the creation of the U.S. SNS. 2023 included a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.
[6] Primarily reflects alliance revenues and royalty revenues.
[7] Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Retacrit, Zirabev, Trazimera and Nivestym.
[8] Reflects product revenues and royalty revenues.
[9] Erbitux® is a registered trademark of ImClone LLC.
[10] Reflects alliance revenues.